Sonnet BioTherapeutics (NASDAQ:SONN – Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.06, Zacks reports. Sonnet BioTherapeutics had a negative return on equity of 382.31% and a negative net margin of 11,187.19%.
Sonnet BioTherapeutics Price Performance
Sonnet BioTherapeutics stock traded down $0.15 during mid-day trading on Friday, reaching $0.66. 733,774 shares of the company’s stock traded hands, compared to its average volume of 90,157. Sonnet BioTherapeutics has a 12-month low of $0.62 and a 12-month high of $8.19. The stock has a 50 day moving average of $1.01 and a two-hundred day moving average of $1.51.
Analyst Upgrades and Downgrades
Separately, Chardan Capital restated a “buy” rating and set a $30.00 price target on shares of Sonnet BioTherapeutics in a report on Tuesday, May 28th.
About Sonnet BioTherapeutics
Sonnet BioTherapeutics Holdings, Inc, a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues.
Recommended Stories
- Five stocks we like better than Sonnet BioTherapeutics
- What is a Low P/E Ratio and What Does it Tell Investors?
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
- What are earnings reports?
- Warren Buffett’s Recent Stock Moves: Top Buys and Sells to Watch
- Retail Stocks Investing, Explained
- Sea Limited’s E-Commerce and Fintech Strength Fuel Stock Surge
Receive News & Ratings for Sonnet BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonnet BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
